The study aims to evaluate the safety and efficacy of VX-121/tezacaftor/deutivacaftor in cystic fibrosis patients.
To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at email@example.com or phone 6151 0888.
Eligibility & Requirements
- Aged 18 or over with a diagnosis of cystic fibrosis
- The total study duration is approximately 64 weeks.
- It involves 13 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands and 6 phone call follow-ups.
Sign up today
Bayesian Evidence-Adaptive Treatment in Cystic Fibrosis (BEAT CF)